EE04453B1 - Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena - Google Patents

Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Info

Publication number
EE04453B1
EE04453B1 EE9700255A EE9700255A EE04453B1 EE 04453 B1 EE04453 B1 EE 04453B1 EE 9700255 A EE9700255 A EE 9700255A EE 9700255 A EE9700255 A EE 9700255A EE 04453 B1 EE04453 B1 EE 04453B1
Authority
EE
Estonia
Prior art keywords
beta
activating agent
lymphotoxin
lhc
carrier
Prior art date
Application number
EE9700255A
Other languages
English (en)
Estonian (et)
Other versions
EE9700255A (et
Inventor
L. Browning Jeffrey
Meier Werner
D. Benjamin Christopher
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9700255A publication Critical patent/EE9700255A/xx
Publication of EE04453B1 publication Critical patent/EE04453B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EE9700255A 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena EE04453B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37896895A 1995-01-26 1995-01-26
PCT/US1996/001386 WO1996022788A1 (en) 1995-01-26 1996-01-26 LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS

Publications (2)

Publication Number Publication Date
EE9700255A EE9700255A (et) 1998-04-15
EE04453B1 true EE04453B1 (et) 2005-04-15

Family

ID=23495285

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700255A EE04453B1 (et) 1995-01-26 1996-01-26 Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena

Country Status (24)

Country Link
EP (2) EP1407781A1 (cs)
JP (2) JPH10513161A (cs)
KR (2) KR100475492B1 (cs)
CN (3) CN1589902A (cs)
AT (1) ATE268604T1 (cs)
AU (1) AU725351B2 (cs)
BG (1) BG62599B1 (cs)
BR (1) BR9606808A (cs)
CA (1) CA2211443A1 (cs)
CZ (1) CZ298711B6 (cs)
DE (1) DE69632681T2 (cs)
DK (1) DK0809510T3 (cs)
EA (1) EA000096B1 (cs)
EE (1) EE04453B1 (cs)
ES (1) ES2220972T3 (cs)
FI (1) FI119359B (cs)
HU (1) HUP9801746A3 (cs)
NO (1) NO322744B1 (cs)
NZ (1) NZ303405A (cs)
PL (1) PL185364B1 (cs)
PT (1) PT809510E (cs)
RO (1) RO118634B1 (cs)
SK (1) SK286497B6 (cs)
WO (1) WO1996022788A1 (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
IL155340A0 (en) * 2000-10-13 2003-11-23 Biogen Inc HUMANIZED ANTI LYMPHOTOXIN-beta-RECEPTOR ANTIBODIES
JP2005532051A (ja) * 2002-07-01 2005-10-27 バイオジェン， インコーポレイテッド ヒト化抗リンホトキシンβレセプター抗体
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
AU2003303339A1 (en) * 2002-12-20 2004-07-22 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN1980957A (zh) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP1764371A1 (de) * 2005-04-25 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
CN101073665B (zh) * 2006-05-17 2014-11-26 上海复旦张江生物医药股份有限公司 淋巴毒素在制备增加化疗药物敏感性的药物中的应用
WO2008042436A2 (en) 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
JP2012504245A (ja) * 2008-09-30 2012-02-16 ジェネンテック， インコーポレイテッド リンホトキシンアンタゴニストに対する関節リウマチの応答性を予測する生物学的マーカー
HK1203309A1 (zh) * 2011-12-05 2015-10-30 Igenica Biotherapeutics, Inc. 抗體-藥物綴合物以及相關化合物、組合物和方法
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
JPS61277628A (ja) * 1985-06-04 1986-12-08 Asahi Chem Ind Co Ltd 癌治療用白血球刺激材
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
DK0536299T3 (da) * 1990-06-27 2001-07-09 Univ California Overfladekompleksbundet lymfotolksin
JPH08507201A (ja) * 1992-12-04 1996-08-06 バイオジェン，インコーポレイテッド リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用

Also Published As

Publication number Publication date
CZ298711B6 (cs) 2008-01-02
HK1006356A1 (en) 1999-02-26
NO973385D0 (no) 1997-07-22
EA000096B1 (ru) 1998-08-27
BG101855A (en) 1998-04-30
FI973118A0 (fi) 1997-07-25
CN1900116A (zh) 2007-01-24
KR20040102364A (ko) 2004-12-04
DE69632681T2 (de) 2005-06-09
BR9606808A (pt) 1997-12-30
KR100470739B1 (ko) 2005-09-02
HUP9801746A2 (hu) 1998-11-30
PL321758A1 (en) 1997-12-22
SK98697A3 (en) 2000-02-14
NO322744B1 (no) 2006-12-04
KR19980701816A (ko) 1998-06-25
WO1996022788A1 (en) 1996-08-01
DE69632681D1 (de) 2004-07-15
EP0809510B1 (en) 2004-06-09
EE9700255A (et) 1998-04-15
NO973385L (no) 1997-09-25
ATE268604T1 (de) 2004-06-15
PT809510E (pt) 2004-09-30
MX9705629A (es) 1997-10-31
CN1589902A (zh) 2005-03-09
JPH10513161A (ja) 1998-12-15
AU4970496A (en) 1996-08-14
CN1146442C (zh) 2004-04-21
ES2220972T3 (es) 2004-12-16
FI973118A7 (fi) 1997-09-25
DK0809510T3 (da) 2004-10-04
CN1177302A (zh) 1998-03-25
EP0809510A1 (en) 1997-12-03
SK286497B6 (sk) 2008-11-06
CZ236197A3 (cs) 1998-02-18
CA2211443A1 (en) 1996-08-01
AU725351B2 (en) 2000-10-12
KR100475492B1 (ko) 2005-03-14
RO118634B1 (ro) 2003-08-29
PL185364B1 (pl) 2003-04-30
NZ303405A (en) 2000-02-28
FI119359B (fi) 2008-10-31
HUP9801746A3 (en) 2000-11-28
EP1407781A1 (en) 2004-04-14
BG62599B1 (bg) 2000-03-31
EA199700144A1 (ru) 1997-12-30
JP2007169296A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
EE9700255A (et) Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ß retseptori antikehad kasvajavastaste agensitena
KIRKPATRICK et al. Stereospecific glucocorticoid binding to subcellular fractions of the sensitive and resistant lymphosarcoma P1798
AU2332188A (en) Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors
YU83600A (sh) Adenozin a3 receptorski modulatori
EP0734264A4 (en) CONNECTIONS SPECIFICALLY BINDING TO COLORECTAL CANCER CELLS AND METHOD FOR THEIR PRODUCTION
IL180924A0 (en) Method for regulating cell proliferation and cell death
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
MX9709324A (es) Compuestos terapeuticos que comprenden anticuerpos anti receptores fc.
Gonzalez et al. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells
ATE202361T1 (de) N6-heterocyclisch-substituierte adenosin-derivate
AU3897999A (en) Multi-analyte diagnostic system and computer implemented process for same
AU5671096A (en) Methods, nucleotide sequences and host cells for assaying ex ogenous and endogenous protease activity
WO1999016888A3 (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
AR021353A1 (es) Proceso para el procesamiento de sacarosa en glucosa.
WO2002053195A3 (en) System for, and method of, irradiating article with x-ray beam
Gulp et al. Transfer ribonucleic acid methylases of HeLa cells
Yuk et al. Changes in the overall extent of protein glycosylation by Chinese hamster ovary cells over the course of batch culture
ES2177554T3 (es) Glicoproteinas bifuncionales con un complemento de carbohidrato modificado, y su uso en la terapia selectiva de tumores.
De Bellis et al. In vitro studies of histone glycation
Maassen et al. Comparison by photoaffinity labeling of the proteins involved in GTP hydrolysis from 70S ribosomes and a 5S RNA-protein complex from bacillus stearothermophilus
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung
AU5101598A (en) Methods and compositions for treating and diagnosing tumors using adenosine receptor activated cells
NO965347L (no) Fremgangsmåte for fremstilling av cytolytiske T-celler som er spesifikke for et peptid/MHC-kompleks
DK1135164T3 (da) Sammensætning til behandling af inflammation

Legal Events

Date Code Title Description
HK1A Erratum in gazette
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100126